In one paragraphArticle in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors.
Piotr GadzińskiChair and Department of Pharmaceutical Technology, Poznan University of Medical Sciences, 3 Rokietnicka Street, 60-806 Poznań, Poland.ORCID 0000-0001-7577-7410 Agnieszka SkotnickaChair and Department of Pharmaceutical Technology, Poznan University of Medical Sciences, 3 Rokietnicka Street, 60-806 Poznań, Poland.ORCID 0000-0003-3452-8754 Natalia LisiakDepartment of Clinical Chemistry and Molecular Diagnostics, Poznan University of Medical Sciences, 3 Rokietnicka Street, 60-806 Poznan, Poland.
Ewa TotońDepartment of Clinical Chemistry and Molecular Diagnostics, Poznan University of Medical Sciences, 3 Rokietnicka Street, 60-806 Poznan, Poland.ORCID 0000-0002-7602-1604 Błażej RubiśDepartment of Clinical Chemistry and Molecular Diagnostics, Poznan University of Medical Sciences, 3 Rokietnicka Street, 60-806 Poznan, Poland.ORCID 0000-0003-1730-0176 Ewa FlorekLaboratory of Environmental Research, Department of Toxicology, Poznan University of Medical Sciences, 3 Rokietnicka Street, 60-806 Poznań, Poland.ORCID 0000-0002-2689-3009 Dariusz T MlynarczykChair and Department of Chemical Technology of Drugs, Poznan University of Medical Sciences, Rokietnicka 3, 60-806 Poznan, Poland.ORCID 0000-0003-3583-0752 Mirosław SzybowiczInstitute of Materials Research and Quantum Engineering, Faculty of Materials Engineering and Technical Physics, Poznań University of Technology, Piotrowo 3, 60-965 Poznań, Poland.ORCID 0000-0001-8933-571X Ewelina NowakInstitute of Materials Research and Quantum Engineering, Faculty of Materials Engineering and Technical Physics, Poznań University of Technology, Piotrowo 3, 60-965 Poznań, Poland.ORCID 0000-0003-0744-5486 Tomasz OsmałekChair and Department of Pharmaceutical Technology, Poznan University of Medical Sciences, 3 Rokietnicka Street, 60-806 Poznań, Poland.ORCID 0000-0002-6939-2888 Funding
National Science Center (Poland) 2020/37/N/NZ7/02553
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
bioavailabilitydrug deliverygellan gumionotropic gelationmodified release
Identifiers
PMID40430861
PMCPMC12115198
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390